Portal de Periódicos da CAPES

Extracorporeal cardiac shock wave therapy ameliorates myocardial ischemia in patients with severe coronary artery disease

2005; Lippincott Williams & Wilkins; Volume: 17; Issue: 1 Linguagem: Inglês

10.1097/00019501-200602000-00011

1473-5830

Yoshihiro Fukumoto, Akira Itô, Toyokazu Uwatoku, Tetsuya Matoba, Takuya Kishi, Haruki Tanaka, Akira Takeshita, Kenji Sunagawa, Hiroaki Shimokawa,

Cardiac electrophysiology and arrhythmias

In Brief Objective Prognosis of severe coronary artery disease with no indication of percutaneous coronary intervention or coronary artery bypass grafting remains poor. We have recently demonstrated that shock wave therapy effectively induces neovascularization and improves myocardial ischemia in a porcine model in vivo. Methods With permission from the Ethical Committee of our Institute, we treated nine patients with end-stage coronary artery disease with no indication of percutaneous coronary intervention or coronary artery bypass grafting (55–82 years old, five men and four women) with our cardiac shock wave therapy (200 shots/spot at 0.09 mJ/mm2 for 20–40 spots, 3 times a week/series). We followed-up the patients at 1, 3, 6, and 12 months after the therapy to examine the amelioration of myocardial ischemia. When needed, shock wave therapy was performed up to three series at 0, and 1, 3 or 6 months. Results The cardiac shock wave therapy improved symptoms (Canadian Cardiovascular Society functional class score, from 2.7±0.2 to 1.8±0.2, P<0.01) and reduced nitroglycerin use (from 5.4±2.5 to 0.3±0.3/week, P<0.05). The treatment also improved myocardial perfusion as assessed by dipyridamole stress thallium scintigraphy (severity score, 25.2±7.2% improvement, P<0.05; extent score, 23.3±9.0% improvement, P=0.10; washout rate, 20±3 to 34±3, P<0.05). Myocardial perfusion was improved only in the ischemic area treated with the therapy. These beneficial effects persisted for 12 months. No procedural complications or adverse effects were noted. Conclusion These results indicate that our extracorporeal cardiac shock wave therapy is an effective and non-invasive treatment for end-stage coronary artery disease, although further careful evaluation is needed. Prognosis of severe coronary artery disease with no indication of percutaneous coronary intervention or coronary artery bypass grafting remains poor. We have recently demonstrated that shock wave therapy effectively induces neovascularization and improvesmyocardial ischemia in a porcinemodel in vivo. The aimof this study was to test this notion in patients with severe coronary artery disease. We treated nine patients with severe coronary artery disease with our cardiac shock wave therapy. We followed-up the patients at 1, 3, 6, and 12 months after the therapy to examine the amelioration ofmyocardial ischemia. When needed, shock wave therapy was performed up to three series at 0, and 1, 3 or 6 months. The cardiac shock wave therapy improved symptoms, nitroglycerin use, andmyocardial perfusion as assessed by dipyridamole stress thallium scintigraphy. These beneficial effects persisted for 12 months. No procedural complications or adverse effects were noted. These results suggest that our extracorporeal cardiac shock wave therapy is an effective and non-invasive treatment for severe coronary artery disease.